Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies.

ABSTRACT:

Introduction

Drug resistance is the main barrier to achieving cancer cures with medical therapy. Cancer drug resistance occurs, in part, due to adaptation of the tumor and microenvironment to therapeutic stress at a proteomic level. Reverse-phase protein arrays (RPPA) are well suited to proteomic analysis of drug resistance due to high sample throughput, sensitive detection of phosphoproteins, and validation for a large number of critical cellular pathways.

Areas covered

This review summarizes contributions of RPPA to understanding and combating drug resistance. In particular, contributions of RPPA to understanding resistance to PARP inhibitors, BRAF inhibitors, immune checkpoint inhibitors, and breast cancer investigational therapies are discussed. Articles reviewed were id

SUBMITTER: Cathcart AM 

PROVIDER: S-EPMC9215307 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature